Phase II trial of outpatient interleukin-2 in malignant lymphoma, chronic lymphocytic leukemia, and selected solid tumors

High-dose interleukin-2 (IL-2) with or without lymphokine-activated killer (LAK) cells has been reported to have activity in certain solid tumors, but toxicity has usually required hospitalization for administration. The purpose of this trial was to determine the antineoplastic effect and toxicity o...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical oncology 1989-01, Vol.7 (1), p.75-80
Hauptverfasser:	Allison, M A, Jones, S E, McGuffey, P
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Drug Evaluation Female Humans Interleukin-2 - adverse effects Interleukin-2 - therapeutic use Leukemia, Lymphocytic, Chronic, B-Cell - mortality Leukemia, Lymphocytic, Chronic, B-Cell - therapy Lymphoma - mortality Lymphoma - therapy Male Middle Aged Neoplasm Metastasis Neoplasms - mortality Neoplasms - therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!